Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Clinical trial design for target-based therapy.

Fox E, Curt GA, Balis FM.

Oncologist. 2002;7(5):401-9. Review.

2.
3.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
4.

Strategy for the development of novel anticancer drugs.

Saijo N, Tamura T, Nishio K.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S97-101. Epub 2003 Jun 18. Review.

PMID:
12856152
5.
6.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
7.

Problems in the development of target-based drugs.

Saijo N, Tamura T, Nishio K.

Cancer Chemother Pharmacol. 2000;46 Suppl:S43-5. Review.

PMID:
10950147
8.

Clinical trial designs for cytostatic agents: are new approaches needed?

Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC.

J Clin Oncol. 2001 Jan 1;19(1):265-72. Review.

PMID:
11134222
9.

Novel anticancer agents in clinical development.

Adjei AA, Rowinsky EK.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S5-15. Review.

PMID:
14508076
10.

The role of emerging genomics and proteomics technologies in cancer drug target discovery.

Onyango P.

Curr Cancer Drug Targets. 2004 Mar;4(2):111-24. Review.

PMID:
15032664
11.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

El-Maraghi RH, Eisenhauer EA.

J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19. Review.

PMID:
18285606
12.

End points in cancer clinical trials and the drug approval process.

Schilsky RL.

Clin Cancer Res. 2002 Apr;8(4):935-8.

13.
14.

Phase II clinical trials in oncology: are we hitting the target?

Ang MK, Tan SB, Lim WT.

Expert Rev Anticancer Ther. 2010 Mar;10(3):427-38. doi: 10.1586/era.09.178. Review.

PMID:
20214523
15.
16.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

17.

Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?

Rixe O, Fojo T.

Clin Cancer Res. 2007 Dec 15;13(24):7280-7. Review.

18.

A design for phase II testing of anticancer agents within a phase III clinical trial.

Schaid DJ, Ingle JN, Wieand S, Ahmann DL.

Control Clin Trials. 1988 Jun;9(2):107-18.

PMID:
3396362
19.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
20.

Satraplatin: BMS 182751, BMY 45594, JM 216.

[No authors listed]

Drugs R D. 2007;8(2):125-32. Review.

PMID:
17324011
Items per page

Supplemental Content

Write to the Help Desk